On June 4, 2023 AskAt reported to have received a communication under Rule 71(3) EPC dated May 19, 2023 from the European Patent Office, with which the grant of the European patent is proposed (Press release, AskAt, JUN 4, 2023, View Source [SID1234632415]). This grant of European Patent Application No. 18191714.7 is an EP4 receptor antagonist use patent for the treatment of cancer, particularly for the use of grapiprant in the treatment of epithelial cancer. AskAt’s EP4 receptor antagonist cancer use patent (Filing Date: April 22, 2010) has already been granted in Japan, the United States, Europe, Canada, China, Korea, Mexico, Brazil, Russia, and Hong Kong. This will reinforce the protection of a
patent in Europe.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!